Home / Market News / $AGEN

$AGEN news and market catalysts

The 22 most recent market catalysts affecting $AGEN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

22 catalysts 4 high impact 17 bullish 1 bearish Biotechnology
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
B. Riley Securities Maintains Agenus at Buy and Raises Price Target
B. Riley Securities maintained its 'Buy' rating on Agenus Inc. and raised its price target from $14 to $16, representing a 14.3% increase. This analyst action is a positive signal …
Nov 6, 2026 Corporate Catalyst Bullish Impact 75
Agenus Reports Long-Term Survival Data for BOT+BAL in Refractory MSS Metastatic Colorectal Cancer at SITC 2026
Agenus presented compelling clinical data at SITC 2026, showing that over 50% of patients with refractory MSS metastatic colorectal cancer treated with BOT+BAL achieved long-term s…
Nov 5, 2026 Corporate Catalyst Bullish Impact 75
Agenus Reports Third Quarter 2026 Financial Results and Operational Updates
Agenus Inc. reported its Q3 2026 financial results, highlighting its third consecutive quarter of positive operating income and $31.5 million in revenue. This financial stability i…
Nov 2, 2026 Corporate Catalyst Neutral Impact 75
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Results
Agenus reported the publication of its Phase 2 UNICORN trial results in Nature Medicine, a highly respected scientific journal. The trial demonstrated that botensilimab, alone or w…
Nov 1, 2026 Corporate Catalyst Bearish Impact 55
HC Wainwright Lowers Price Target for Agenus Inc.
HC Wainwright, a financial services firm, has updated its analyst review for Agenus Inc., resulting in a downward revision of the company's price target from $30 to $25. This chang…
Oct 26, 2026 Corporate Catalyst Bullish Impact 85
Agenus Reports Positive Phase 2 Results for BOT+BAL in NEOASIS Study at ESMO 2026
Agenus reported compelling early Phase 2 results for its BOT+BAL combination therapy in dMMR colon cancer, with 72% of patients achieving no remaining cancer after treatment. This …
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer
Agenus has received its first global marketing authorizations for Botvymo and Evamplix in Armenia for the treatment of metastatic colorectal cancer. This is a positive development …
Oct 5, 2026 Corporate Catalyst Bullish Impact 75
Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients
Agenus announced encouraging long-term survival data for its BOT+BAL combination therapy in recurrent ovarian cancer. The 48% estimated three-year survival rate and the fact that 2…
Sep 28, 2026 Corporate Catalyst Bullish Impact 75
Agenus shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $19 price target.
This headline represents a significant corporate catalyst for Agenus. Analyst initiations with 'Buy' ratings and ambitious price targets often lead to immediate positive stock pric…
Sep 28, 2026 Corporate Catalyst Neutral Impact 65
Rodman & Renshaw Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $19
Rodman & Renshaw's initiation of coverage on Agenus with a 'Buy' rating and a $19 price target is a positive development for the company. Analyst coverage, especially with a 'Buy' …
Sep 18, 2026 Corporate Catalyst Neutral Impact 65
Chardan Capital Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $40
Chardan Capital's initiation of coverage on Agenus with a 'Buy' rating and a $40 price target is a positive development for the company. Analyst coverage, especially with a favorab…
Aug 28, 2026 Corporate Catalyst Bullish Impact 75
Agenus Says Published Phase 1b Data Showed 21.2-Month Median Overall Survival, 33% Three-Year Overall Survival And 21% Objective Response Rate With Botensilimab Plus Balstilimab In 123 Pretreated MSS Colorectal Cancer Patients
The positive Phase 1b data for Agenus's botensilimab plus balstilimab in pretreated MSS colorectal cancer patients is a significant corporate catalyst. The reported 21.2-month medi…
Aug 7, 2026 Corporate Catalyst Neutral Impact 65
Agenus Offers Up To 77,976,718 Shares Of Common Stock By Selling Securityholders
Agenus has filed an 8-K indicating that selling securityholders are offering a substantial number of common shares, up to 77,976,718. This is a secondary offering, which means the …
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
Agenus Q2 Sales $34.500M Beat $34.000M Estimate
Agenus announced its Q2 sales, which came in at $34.5 million, surpassing the consensus estimate of $34.0 million. More significantly, this represents a 34.24% increase compared to…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Agenus shares are trading higher after B. Riley Securities raised its price target on the stock from $8 to $14.
The substantial increase in Agenus's price target from $8 to $14 by B. Riley Securities is a significant positive catalyst for the stock. This upgrade suggests that the analyst fir…
Jul 30, 2026 Corporate Catalyst Bullish Impact 65
B. Riley Securities Maintains Buy on Agenus, Raises Price Target to $14
B. Riley Securities analyst Mayank Mamtani has maintained a 'Buy' rating on Agenus and raised the price target from $8 to $14. This substantial increase in the price target, nearly…
Jul 13, 2026 Market Technicals Bullish Impact 60
12 Health Care Stocks Moving In Monday's Intraday Session
This filing, generated by an automated content engine, simply reports the intraday price movements of 12 healthcare stocks. It doesn't disclose any specific corporate catalysts, ne…
Jul 13, 2026 Corporate Catalyst Bullish Impact 65
HC Wainwright & Co. Maintains Buy on Agenus, Raises Price Target to $30
HC Wainwright & Co. analyst Emily Bodnar has maintained a 'Buy' rating on Agenus (AGEN) and raised the price target from $23 to $30. This upgrade signals increased confidence from …
Jul 13, 2026 Corporate Catalyst Bullish Impact 95
Why Is Agenus Stock Gaining Monday?
Agenus's stock surged over 111% following the release of compelling three-year Phase 1b data for its botensilimab plus balstilimab combination in refractory metastatic colorectal c…
Jul 13, 2026 Corporate Catalyst Bullish Impact 95
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
Agenus secured a substantial private placement of $85 million, with the potential for an additional $255 million through warrant exercises, extending its cash runway to 2031. Cruci…
Jul 13, 2026 Corporate Catalyst Bullish Impact 75
Agenus shares are trading higher safter the company announced it will raise $85 million to fund its colon cancer drug trial.
This headline is a significant corporate catalyst for Agenus. The successful $85 million capital raise provides crucial funding for its colon cancer drug trial, alleviating immedia…
Jul 13, 2026 Corporate Catalyst Bullish Impact 85
Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised
Agenus Inc. has secured a significant financing package, starting with $85 million upfront and potentially reaching $340 million through warrant exercises. This capital infusion is…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.